AZN astrazeneca.com: מדד נזילות מהירה

The current quick liquidity ratio reflects the ESG transformation of AstraZeneca PLC (AZN), which aims for full decarbonization and the greening of production facilities. The 0.67 level captures the current state of financial stability, underpinned by strong pricing power in oncology and exclusive patents. This stability is further supported by efficient trial outsourcing and flexible collaboration with contract organizations for global supplies.

This metric excludes illiquid inventories, focusing on the sum of cash and accounts receivable relative to short-term liabilities. It determines the company's ability to instantly settle debts without liquidating warehouse stock. For AstraZeneca PLC (AZN), with its colossal R&D expenditures, such solvency is critical when financing breakthrough developments. The trend of the quick ratio confirms the financial stability of this biopharma behemoth.